0000899243-22-037475.txt : 20221202
0000899243-22-037475.hdr.sgml : 20221202
20221202174856
ACCESSION NUMBER: 0000899243-22-037475
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221130
FILED AS OF DATE: 20221202
DATE AS OF CHANGE: 20221202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harrison Seth Loring
CENTRAL INDEX KEY: 0001404955
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 221443196
MAIL ADDRESS:
STREET 1: 230 PARK AVENUE, SUITE 2800
CITY: NEW YORK
STATE: NY
ZIP: 10169
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-30
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001404955
Harrison Seth Loring
C/O AKERO THERAPEUTICS, INC.,
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2022-11-30
4
S
0
6322
46.4355
D
141080
D
Common Stock
2022-11-30
4
S
0
4779
47.6044
D
136301
D
Common Stock
2022-11-30
4
S
0
6851
46.4355
D
153242
I
See Footnote
Common Stock
2022-11-30
4
S
0
5179
47.6044
D
148063
I
See Footnote
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.28 to $47.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $47.93, inclusive.
Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Jonathan Young, attorney-in-fact
2022-12-02